Augmentation Strategies for Duloxetine in Major Depressive Disorder

Introduction to Augmentation

• The American College of Physicians recommends augmentation with bupropion as the most strongly supported strategy when duloxetine monotherapy fails to achieve remission in major depressive disorder, based on the highest quality evidence 1

Second-Step Treatment Strategy: Augmentation vs. Switching

• Augmentation and switching strategies show similar efficacy when initial antidepressant treatment fails, according to the 2023 American College of Physicians guideline analyzing the landmark STAR*D trial 1
• Bupropion SR augmentation demonstrated equivalent efficacy to buspirone augmentation in the STAR*D trial, but with significantly better tolerability (12.5% vs. 20.6% discontinuation due to adverse events, P < 0.001) 1

Alternative Augmentation Options

• Aripiprazole augmentation showed numerically higher remission rates than bupropion (55.4% vs. 34.0%, P = 0.031) in one trial, though this study had higher risk of bias 1
• Mirtazapine augmentation can be considered, as trials showed no difference between switching to mirtazapine versus augmenting with it, suggesting augmentation is a viable strategy 1

When to Consider Switching Instead

• Switch to a different antidepressant if there is no response after 8 weeks at therapeutic duloxetine doses 2
• Switch to a different antidepressant if there are intolerable side effects from duloxetine (particularly sustained hypertension, given duloxetine's propensity to increase blood pressure) 2
• The STAR*D trial found no efficacy differences between switching to bupropion SR, escitalopram, sertraline, or venlafaxine 1

Critical Monitoring Considerations

• Monitor blood pressure and pulse regularly, as duloxetine can cause sustained hypertension 2
• Assess for serotonin syndrome risk, particularly when combining serotonergic agents 2
• Screen for suicidal ideation, especially in patients under age 24 and during the first weeks after medication changes 2
• Evaluate treatment response after 8 weeks of adequate dosing before declaring treatment failure 2

Common Pitfalls to Avoid

• Do not combine duloxetine with MAOIs due to serotonin syndrome risk 2
• Avoid abrupt discontinuation of duloxetine if switching; taper slowly to prevent discontinuation syndrome 2
• Do not assume all augmentation strategies are equal; bupropion has the best tolerability profile among medication augmentation options 1
• Recognize that cognitive therapy augmentation showed similar efficacy to medication augmentation in STAR*D, with numerically lower discontinuation rates (9.2% vs. 18.8%, P = 0.086) 1